Caffeine-potentiated chemotherapy for patients with high-grade soft tissue sarcoma: Long-term clinical outcome

Anticancer Research

Volumn 27, Issue 5 B, 2007, Pages 3489-3495

  Takeuchi, Akihiko ^a   Tsuchiya, Hiroyuki ^a   Yamamoto, Norio ^a   Hayashi, Katsuhiro ^a   Yamauchi, Kensuke ^a   Kawahara, Masami ^b   Miyamoto, Ken Ichi ^b   Tomita, Katsuro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Caffeine; Chemotherapy; Clinical outcome; Response; Soft tissue sarcoma

Indexed keywords

CAFFEINE; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; XANTHINE OXIDASE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG POTENTIATION; FOLLOW UP; HEART PALPITATION; HISTOLOGY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; NAUSEA; PRIORITY JOURNAL; RADIATION DOSE; SOFT TISSUE SARCOMA; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAFFEINE; CHILD; DISEASE-FREE SURVIVAL; DRUG SYNERGISM; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; NEOPLASM STAGING; PREOPERATIVE CARE; SARCOMA; TIME FACTORS; TREATMENT OUTCOME;

EID: 35348965187     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S and Goodnight J: Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol 5: 21-26, 1987.
2. Jurgens H, Exner U, Gadner H, Harms D, Michaelis J, Sauer R, Treuner J, Voute T, Winkelmann W and Winkler K: Multidisciplinary treatment of primary Ewing's sarcoma of bone. A 6-year experience of a European Cooperative Trial. Cancer 61: 23-32, 1988.
3. Pezzi CM, Pollock RE, Evans HL, Lorigan JG, Pezzi TA, Benjamin RS and Romsdahl MM: Preoperative chemotherapy for soft-tissue sarcomas of the extremities. Ann Surg 211: 476-481, 1990.
4. Pisters PW, Patel SR, Varma DG, Cheng SC, Chen NP, Nguyen HT, Feig BW, Pollack A, Pollock RE and Benjamin RS: Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J Clin Oncol 15: 3481-3487, 1997.
5. Meric F, Hess KR, Varma DG, Hunt KK, Pisters PW, Milas KM, Patel SR, Benjamin RS, Plager C, Papadopoulos NE, Burgess MA, Pollock RE and Feig BW: Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95: 1120-1126, 2002.
6. Gortzak E, Azzarelli A, Buesa J, Bramwell VH, van Coevorden F, van Geel AN, Ezzat A, Santoro A, Oosterhuis JW, van Glabbeke M, Kirkpatrick A and Verweij J: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37: 1096-1103, 2001.
7. Eilber FC, Rosen G, Eckardt J, Forscher C, Nelson SD, Selch M, Dorey F and Eilber FR: Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J Clin Oncol 19: 3203-3209, 2001.
8. Tsuchiya H, Tomita K, Yamamoto N, Mori Y and Asada N: Caffeine-potentiated chemotherapy and conservative surgery for high-grade soft-tissue sarcoma. Anticancer Res 18: 3651-3656, 1998.
9. Tsuchiya H, Yamamoto N, Asada N, Terasaki T, Kanazawa Y, Takanaka T, Nishijima H and Tomita K: Caffeine-potentiated radiochemotherapy and function-saving surgery for high-grade soft tissue sarcoma. Anticancer Res 20: 2137-2143, 2000.
10. Tsuchiya H and Tomita K: The combined effect of anti-tumor agents with caffeine or calcium channel blockers on sarcoma cells by clonogenic assay. Nippon Gan Chiryo Gakkai Shi 22: 1003-1012, 1987 (in Japanese).
11. Tsuchiya H and Tomita K: The combined effect of cisplatin and caffeine on human sarcoma cells in vitro. Gan To Kagaku Ryoho 14: 3125-3130, 1987 (in Japanese).
12. Tomita K and Tsuchiya H: Enhancement of cytocidal and antitumor effect of cisplatin by caffeine in human osteosarcoma. Clin Ther 11: 43-52, 1989.
13. Tomita K and Tsuchiya H: Caffeine enhancement of the effect of anticancer agents on human sarcoma cells. Jpn J Cancer Res 80: 83-88, 1989.
14. Greene FL, Page DL, Fleming ID, Fritz AG, Balch ChM, Haller DG and Morrow M (eds.): American Joint Committee on Cancer Staging Manual (6th ed.). Philadelphia: Springer, 2002.
15. Sobin LH and Wittekind Ch (eds.): TNM Classification of Malignant Tumors (5th ed.). New York: John Wiley & Sons Inc., 1997.
16. Kawahara M, Kagiyama H, Kanazawa Y, Tsuchiya H, Tomita K, Yokogawa K and Miyamoto K: Rapid determination method of caffeine and application to monitoring of caffeine-assisted chemotherapy. Biopharm Drug Dispos 25: 61-67, 2004.
17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
18. Kaplan EL and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
19. Byfield JE, Murnane J, Ward JF, Calabro-Jones P, Lynch M and Kulhanian F: Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents. Br J Cancer 43: 669-683, 1981.
20. Van Den Berg HW and Roberts JJ: Inhibition by caffeine of post-replication repair in Chinese hamster cells treated with eis platinum (II) diamminedichloride: the extent of platinum binding to template DNA in relation to the size of low molecular weight nascent DNA. Chem Biol Interact 12: 375-390, 1976.
21. Yasutake H, Tsuchiya H, Tomita K, Matsunaga T, Nikaido O and Mori T: Inhibitory effect of caffeine on potentially lethal damage repair in cisplatin-treated human osteosarcoma cells. Anticancer Res 15: 831-837, 1995.
22. Tsuchiya H, Tomita K, Mori Y, Asada N, Morinaga T, Kitano S and Yamamoto N: Caffeine-assisted chemotherapy and minimized tumor excision for nonmetastatic osteosarcoma. Anticancer Res 18: 657-666, 1998.
23. Tsuchiya H, Tomita K, Mori Y, Asada N and Yamamoto N: Marginal excision for osteosarcoma with caffeine assisted chemotherapy. Clin Orthop Relat Res 358: 27-35, 1999.
24. Kanazawa Y, Tsuchiya H, Nonomura A, Takazawa K, Yamamoto N and Tomita K: Intentional marginal excision of osteosarcoma of the proximal fibula to preserve limb function. J Orthop Sci 8: 757-761, 2003.
25. Hayashi M, Tsuchiya H, Yamamoto N, Karita M, Shirai T, Nishida H, Takeuchi A and Tomita K: Caffeine-potentiated chemotherapy for metastatic carcinoma and lymphoma of bone and soft tissue. Anticancer Res 25: 2399-2405, 2005.
26. Frustaci S, Gherlinzoni F, De Paoli A, Bonetti M, Azzarelli A, Comandone A, Olmi P, Buonadonna A, Pignatti G, Barbieri E, Apice G, Zmerly H, Serraino D and Picci P: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19: 1238-1247, 2001.
27. Petrioli R, Coratti A, Correale P, D'Aniello C, Grimaldi L, Tanzini G, Civitelli S, Marsili S, Messinese S, Marzocca G, Pirtoli L and Francini G: Adjuvant epirubicin with or without Ifosfamide for adult soft-tissue sarcoma. Am J Clin Oncol 25: 468-473, 2002.